Lerodalcibep (LEROCHOL)

About LIB Therapeutics

LIB Therapeutics is a clinical-stage biotech advancing lerodalcibep, a next-generation PCSK9 inhibitor, through Phase 3 trials for atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH). Its key differentiator is a patient-centric formulation offering once-monthly dosing with a small injection volume and long ambient stability, potentially improving adherence over existing biweekly PCSK9 inhibitors. The company is targeting a massive and growing global market of over 100 million patients with clinically significant ASCVD. As a private, commercial-stage company, its near-term value inflection hinges on successful Phase 3 data and subsequent regulatory approval and commercialization of lerodalcibep.

Therapeutic Areas